ROCHESTER, N.Y. — Bausch + Lomb, the global eye health company,
announces the appointment of David Mordaunt, Ph.D. as vice president,
Development and Research, Bausch + Lomb Surgical.
In this position, Dr. Mordaunt will be a member of the Surgical senior
leadership team and will be responsible for global strategies and
execution of development and research programs for the full portfolio of
products. This includes equipment used for cataract and vitroretinal
procedures, intraocular lenses including Crystalens®, which is
the only FDA-approved accommodating intraocular lens offering a full
range of natural vision, viscoelastics and new technologies focused on
enhancing ophthalmologists ability to offer patient-centric procedures.
“I’m thrilled to be joining Bausch + Lomb Surgical," said Dr. Mordaunt.
"They have a strong pipeline for innovative new technologies focused on
improving ophthalmic surgical outcomes, which enhance patient vision and
quality of life. I look forward to collaborating with the ophthalmic
physician community to continue to advance Bausch + Lomb’s product
“Dr. Mordaunt’s proven leadership in the development of transformational
new product technologies in ophthalmology is well known”, said Robert
Grant, CEO and president, Bausch + Lomb Surgical. “We look forward to
his experience and leadership in advancing products to benefit the
physician and patient community we serve.”
Dr. Mordaunt is a recognized expert in the medical device industry for
the development of innovative technologies that have changed the
standard of patient care. These technologies include Pattern Scanning
Laser (PASCAL) for diabetic retinopathy, Selective Laser Trabeculoplasty
(SLT) for glaucoma and Photodynamic Therapy (PDT) for macular
Dr. Mordaunt has held positions of director, surgical R&D for
Coherent, Inc.; vice president of R&D for Lumenis; and chief
executive officer, president and co-founder of OPTIMEDICA Corp., which
focuses on the treatment of diabetic retinopathy, glaucoma and cataract
diseases. Most recently, Dr. Mordaunt was chief executive officer of
Precision Light, which developed the foundation technologies for 4D
imaging and evidenced-based outcome simulation in plastic surgery.
Dr. Mordaunt holds a bachelor of science and a doctorate degree in
chemical physics, physics and chemistry from the University of Bristol,
England. He was also awarded prestigious fellowships and held positions
at the Max-Plank Institute in Gottingen, Germany, and the University of
California at Berkeley.
Dr. Mordaunt will be based in Aliso Viejo, California.
About Bausch + Lomb
Bausch + Lomb is one of the best-known and most respected healthcare
companies in the world. Its core businesses include contact lenses and
lens care products, ophthalmic surgical devices and instruments, and
ophthalmic pharmaceuticals. Founded in 1853, the company is
headquartered in Rochester, N.Y., and employs more than 10,000 people
worldwide. Its products are available in more than 100 countries. More
information is available at www.bausch.com.
Crystalens is a registered trademark of Bausch + Lomb.